- Home
- IGMS vs XCUR Comparison
IGMS vs XCUR Comparison
Compare IGMS & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- XCUR
- Stock Information
- Founded
- IGMS 1993
- XCUR 2011
- Country
- IGMS United States
- XCUR United States
- Employees
- IGMS N/A
- XCUR N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- XCUR Health Care
- Exchange
- IGMS Nasdaq
- XCUR Nasdaq
- Market Cap
- IGMS 82.1M
- XCUR 74.1M
- IPO Year
- IGMS 2019
- XCUR N/A
- Fundamental
- Price
- IGMS $1.18
- XCUR $11.38
- Analyst Decision
- IGMS Hold
- XCUR
- Analyst Count
- IGMS 8
- XCUR 0
- Target Price
- IGMS $6.14
- XCUR N/A
- AVG Volume (30 Days)
- IGMS 155.8K
- XCUR 31.6K
- Earning Date
- IGMS 05-20-2025
- XCUR 06-16-2025
- Dividend Yield
- IGMS N/A
- XCUR N/A
- EPS Growth
- IGMS N/A
- XCUR N/A
- EPS
- IGMS N/A
- XCUR N/A
- Revenue
- IGMS $2,679,000.00
- XCUR $500,000.00
- Revenue This Year
- IGMS $121.76
- XCUR N/A
- Revenue Next Year
- IGMS $46.83
- XCUR N/A
- P/E Ratio
- IGMS N/A
- XCUR N/A
- Revenue Growth
- IGMS 25.77
- XCUR N/A
- 52 Week Low
- IGMS $0.92
- XCUR $1.44
- 52 Week High
- IGMS $22.50
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- IGMS 39.53
- XCUR 51.56
- Support Level
- IGMS $1.11
- XCUR $9.81
- Resistance Level
- IGMS $1.40
- XCUR $11.58
- Average True Range (ATR)
- IGMS 0.11
- XCUR 1.00
- MACD
- IGMS -0.01
- XCUR 0.02
- Stochastic Oscillator
- IGMS 5.56
- XCUR 58.32
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.